WallStreetZenWallStreetZen

NASDAQ: KMDA
Kamada Ltd Stock

$4.51-0.18 (-3.84%)
Updated Feb 6, 2023
KMDA Price
$4.51
Fair Value Price
$4.93
Market Cap
$202.05M
52 Week Low
$3.72
52 Week High
$6.18
P/E
-19.61x
P/B
1.17x
P/S
1.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$115.37M
Earnings
-$10.27M
Gross Margin
32.9%
Operating Margin
-7.92%
Profit Margin
-8.9%
Debt to Equity
0.85
Operating Cash Flow
$17M
Beta
0.5
Next Earnings
Mar 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A

KMDA Overview

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KMDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KMDA ($4.51) is undervalued by 8.46% relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KMDA ($4.51) is not significantly undervalued (8.46%) relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KMDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KMDA due diligence checks available for Premium users.

Be the first to know about important KMDA news, forecast changes, insider trades & much more!

KMDA News

Valuation

KMDA fair value

Fair Value of KMDA stock based on Discounted Cash Flow (DCF)
Price
$4.51
Fair Value
$4.93
Undervalued by
8.46%
KMDA ($4.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KMDA ($4.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KMDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KMDA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-19.61x
Industry
18.21x
Market
14.99x

KMDA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
1.9x
KMDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KMDA's financial health

Profit margin

Revenue
$32.2M
Net Income
$484.0k
Profit Margin
1.5%
KMDA's Earnings (EBIT) of -$9.13M... subscribe to Premium to read more.
Interest Coverage Financials
KMDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$319.6M
Liabilities
$147.1M
Debt to equity
0.85
KMDA's short-term assets ($135.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KMDA's short-term assets ($135.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KMDA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KMDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$5.5M
Investing
-$1.6M
Financing
-$2.3M
KMDA's operating cash flow ($16.88M)... subscribe to Premium to read more.
Debt Coverage Financials

KMDA vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
KMDA$202.05M-3.84%-19.61x1.17x
ASRT$201.87M+1.95%7.33x1.50x
BGXX$199.82M-7.09%N/A15.20x
XXII$221.76M-2.83%-3.96x1.83x
INCR$168.35M+0.54%15.61x1.31x

Kamada Stock FAQ

What is Kamada's quote symbol?

NASDAQ: KMDA) Kamada trades on the NASDAQ under the ticker symbol KMDA. Kamada stock quotes can also be displayed as NASDAQ: KMDA.

If you're new to stock investing, here's how to buy Kamada stock.

What is the 52 week high and low for Kamada (NASDAQ: KMDA)?

(NASDAQ: KMDA) Kamada's 52-week high was $6.18, and its 52-week low was $3.72. It is currently -27.02% from its 52-week high and 21.2% from its 52-week low.

How much is Kamada stock worth today?

(NASDAQ: KMDA) Kamada currently has 44,799,794 outstanding shares. With Kamada stock trading at $4.51 per share, the total value of Kamada stock (market capitalization) is $202.05M.

Kamada stock was originally listed at a price of $10.10 in May 31, 2013. If you had invested in Kamada stock at $10.10, your return over the last 9 years would have been -55.35%, for an annualized return of -8.57% (not including any dividends or dividend reinvestments).

How much is Kamada's stock price per share?

(NASDAQ: KMDA) Kamada stock price per share is $4.51 today (as of Feb 6, 2023).

What is Kamada's Market Cap?

(NASDAQ: KMDA) Kamada's market cap is $202.05M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kamada's market cap is calculated by multiplying KMDA's current stock price of $4.51 by KMDA's total outstanding shares of 44,799,794.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.